PMV Pharmaceuticals reports 46% ORR and plans Q1 2027 NDA filing
PMV Pharmaceuticals says its ovarian cohort generated a 46% ORR and it plans an NDA filing in Q1 2027.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
PMV Pharmaceuticals says its ovarian cohort generated a 46% ORR and it plans an NDA filing in Q1 2027.